UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 76

Sortiert nach

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

The Lancet (British edition), 2000-03, Vol.355 (9209), p.1035-1040

2000

Volltextzugriff (PDF)

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonist

Alimentary pharmacology & therapeutics, 1999-09, Vol.13 (9), p.1149-1159

1999

Volltextzugriff (PDF)

Gastrointestinal side effects in chronic opioid users: results from a population‐based survey

Alimentary pharmacology & therapeutics, 2008-06, Vol.27 (12), p.1224-1232

2008

Volltextzugriff (PDF)

Prevalence and demographics of irritable bowel syndrome: results from a large web‐based survey

Alimentary pharmacology & therapeutics, 2005-11, Vol.22 (10), p.935-942

2005

Volltextzugriff (PDF)

Clinical trial: dextofisopam in the treatment of patients with diarrhoea‐predominant or alternating irritable bowel syndrome

Alimentary pharmacology & therapeutics, 2008-01, Vol.27 (2), p.197-206

2008

Volltextzugriff (PDF)

Primary Endpoints for Irritable Bowel Syndrome Trials: A Review of Performance of Endpoints

Clinical gastroenterology and hepatology, 2007-05, Vol.5 (5), p.534-540

2007

Volltextzugriff (PDF)

Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence

Patient preference and adherence, 2016-01, Vol.10 (Issue 1), p.1025-1035

2016

Volltextzugriff (PDF)

Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review

Clinical and experimental gastroenterology, 2012-01, Vol.5 (default), p.1-10

2012

Volltextzugriff (PDF)

Personal view: adequate relief as a primary endpoint in irritable bowel syndrome

Alimentary pharmacology & therapeutics, 2006-04, Vol.23 (7), p.879-881

MANGEL, A. W.

2006

Volltextzugriff (PDF)

Impact of patient adherence on the cost-effectiveness of noninvasive tests for the initial diagnosis of Helicobacter pylori infection in the United States

Patient preference and adherence, 2016-01, Vol.10 (Issue 1), p.45-55

2016

Volltextzugriff (PDF)

Determinants of healthcare‐seeking behaviour among subjects with irritable bowel syndrome

Alimentary pharmacology & therapeutics, 2006-06, Vol.23 (11), p.1667-1675

2006

Volltextzugriff (PDF)

From depolarization-dependent contractions in gastrointestinal smooth muscle to aortic pulse-synchronized contractions

Clinical and Experimental Gastroenterology, 2014-01, Vol.7 (default), p.61-66

2014

Volltextzugriff (PDF)

A dose‐ranging, placebo‐controlled, randomized trial of alosetron in patients with functional dyspepsia

Alimentary pharmacology & therapeutics, 2001-04, Vol.15 (4), p.525-537

2001

Volltextzugriff (PDF)

Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists

Neurogastroenterology and motility, 2008-10, Vol.20 (10), p.1086-1093

2008

Volltextzugriff (PDF)

Postinfectious IBS

The American journal of gastroenterology, 2005-03, Vol.100 (3), p.729-729

Mangel, Allen W

2005

Volltextzugriff (PDF)

Study design issues in irritable bowel syndrome

Alimentary pharmacology & therapeutics, 2004-01, Vol.19 (1), p.141-142

Mangel, A. W.

2004

Volltextzugriff (PDF)

Stability of irritable bowel syndrome using a Rome II‐based classification

Alimentary pharmacology & therapeutics, 2006-01, Vol.23 (1), p.197-205

2006

Volltextzugriff (PDF)

Assessment of treatment response in chronic constipation clinical trials

Clinical and experimental gastroenterology, 2014, Vol.7 (default), p.191-198

2014

Volltextzugriff (PDF)

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome

The American journal of gastroenterology, 2001-02, Vol.96 (2), p.455-459

2001

Volltextzugriff (PDF)

Review article: the safety and efficacy of alosetron, a 5‐HT3 receptor antagonist, in female irritable bowel syndrome patients

Alimentary pharmacology & therapeutics, 1999-05, Vol.13, p.77-82

1999

Volltextzugriff (PDF)

Mice lacking the dopamine transporter display altered regulation of distal colonic motility

American journal of physiology: Gastrointestinal and liver physiology, 2000-08, Vol.279 (2), p.G311-G318

2000

Volltextzugriff (PDF)

Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria

The American journal of gastroenterology, 1999-05, Vol.94 (5), p.1279-1282

1999

Volltextzugriff (PDF)

Global endpoints in functional gastrointestinal disease

Alimentary pharmacology & therapeutics, 2005-12, Vol.22 (11‐12), p.1162-1163

2005

Volltextzugriff (PDF)

Adequate relief as an endpoint in clinical trials in irritable bowel syndrome

Journal of international medical research, 1998-03, Vol.26 (2), p.76

1998

Volltextzugriff (PDF)

Calcium-dependent, swelling-activated K + conductance in human neuroblastoma cells

Biochemical and biophysical research communications, 2003-09, Vol.308 (4), p.759-763

2003

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(76)

Sprache

Englisch
(76)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(74)
Life Sciences & Biomedicine
(73)
Animals
(38)
Gastroenterology & Hepatology
(33)
Humans
(29)
Biological And Medical Sciences
(27)
Pharmacology & Pharmacy
(25)
Physiology
(21)
Male
(16)
Medical Sciences
(16)
Digestive System
(15)
Pharmacology. Drug Treatments
(15)
Calcium - Metabolism
(14)
Cats
(13)
Female
(13)
In Vitro Techniques
(12)
Calcium - Physiology
(11)
Fundamental And Applied Biological Sciences. Psychology
(11)
Mice
(11)
Adult
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonist

Gastrointestinal side effects in chronic opioid users: results from a population‐based survey

Prevalence and demographics of irritable bowel syndrome: results from a large web‐based survey

Clinical trial: dextofisopam in the treatment of patients with diarrhoea‐predominant or alternating irritable bowel syndrome

Primary Endpoints for Irritable Bowel Syndrome Trials: A Review of Performance of Endpoints

Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence

Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review

Personal view: adequate relief as a primary endpoint in irritable bowel syndrome

Impact of patient adherence on the cost-effectiveness of noninvasive tests for the initial diagnosis of Helicobacter pylori infection in the United States

Determinants of healthcare‐seeking behaviour among subjects with irritable bowel syndrome

From depolarization-dependent contractions in gastrointestinal smooth muscle to aortic pulse-synchronized contractions

A dose‐ranging, placebo‐controlled, randomized trial of alosetron in patients with functional dyspepsia

Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists

Postinfectious IBS

Study design issues in irritable bowel syndrome

Stability of irritable bowel syndrome using a Rome II‐based classification

Assessment of treatment response in chronic constipation clinical trials

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome

Review article: the safety and efficacy of alosetron, a 5‐HT3 receptor antagonist, in female irritable bowel syndrome patients

Mice lacking the dopamine transporter display altered regulation of distal colonic motility

Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria

Global endpoints in functional gastrointestinal disease

Adequate relief as an endpoint in clinical trials in irritable bowel syndrome

Calcium-dependent, swelling-activated K + conductance in human neuroblastoma cells

Suchergebnisse filtern